pyrimidinones and End-Stage-Liver-Disease

We conducted an exploratory study to assess the safety tolerability, and anti-fibrotic effects of PRI-724, a CBP/β-catenin inhibitor, in patients with hepatitis C virus (HCV)- and hepatitis B virus (HBV)-induced cirrhosis.. Three patients from phase 1 who received the recommended PRI-724 dose were evaluated to obtain efficacy and safety data in phase 2a. Serious adverse events occurred in three patients, one of which was possibly related to PRI-724. The most common adverse events were diarrhoea and nausea. PRI-724 did not decrease hepatic fibrosis with any statistical significance, either by ordinal scoring or measurement of collagen proportionate area at 12 weeks; however, we observed statistically significant improvements in liver stiffness, Model for End-stage Liver Disease score, and serum albumin level.. AMED, Ohara Pharmaceutical.

Topics: Antiviral Agents; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; End Stage Liver Disease; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Herpesvirus 1, Cercopithecine; Humans; Liver Cirrhosis; Pyrimidinones; Severity of Illness Index; Treatment Outcome

To investigate the efficacy of antiviral treatment on patients with acute-on-chronic hepatitis B liver failure with low viral load.. 352 patients with acute-on-chronic hepatitis B liver failure including 175 cases of low HBV viral load and 177 cases of high HBV viral load were enrolled into this study. The patients were divided into the antiviral group which received antiviral therapy (Lamivudine, Entecavir or Telbivudine) plus routine supportive therapy and the control group which received supportive therapy only. The clinical features and the 24-week short-term efficacy of antiviral therapy were assessed.. At week 24,total survival rate in antiviral group was higher than that in control group (P = 0.010). The survival rate of patients with low viral load in the antiviral group was higher than that in the control group (P = 0.001). But there was no significant difference between the antiviral group and the control group with high viral load (P = 0.856). But in the antiviral group, there was no significant difference in survival rate between the patients with high HBV viral load and those with low viral load (P = 0.755).. Antiviral therapy can significantly improve survival rate of patients of acute-on-chronic hepatitis B liver failure with low viral load. Liver failure;

Topics: Adult; Antiviral Agents; End Stage Liver Disease; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure, Acute; Male; Middle Aged; Nucleosides; Pyrimidinones; Telbivudine; Thymidine; Viral Load